Re: IMPORTANT: New drug AZD2171
Posted: Thu Nov 06, 2008 11:59 am
Dear Paul,
Thank you for your thoughtful update and for sharing this wonderful and VERY encouraging news. We are SO Hopeful that the treatment will provide continued stabilization of your disease, and will look forward to your next update. We are Hoping that a
Phase 2 AZD2171 Clinical Trial will become available for ASPS patients in the United States sometime very soon as it certainly seems to offer great promise. Unfortunately, as Olga has indicated, the very few currently available Cediranib Clinical Trials in the United States do not include ASPS patients or have age restrictions and/or have preclusion criteria for patients with brain mets. It is my understanding that you had existing brain mets when you enrolled in the AZD2171 Clinical Trial in London. Had your brain mets been treated with radiation, Gamma Knife, or other radiosurgery so that you had proven three month brain met stability as is required by the Cediranib Clinical Trial in Canada? We will continue to closely follow the results of your continued AZD2171 treatment and any other ASPS patients participating in Cediranib Clinical Trials, and will hold very tight to Hope that this promising new treatment will prove to be the effective systemic treatment and cure which we are all seeking. In the meantime, please take care Paul, know that my and my family's special thoughts and best wishes are with you, and keep in touch with the Web site as you are able.
With special caring thoughts and continued Hope,
Bonni
Thank you for your thoughtful update and for sharing this wonderful and VERY encouraging news. We are SO Hopeful that the treatment will provide continued stabilization of your disease, and will look forward to your next update. We are Hoping that a
Phase 2 AZD2171 Clinical Trial will become available for ASPS patients in the United States sometime very soon as it certainly seems to offer great promise. Unfortunately, as Olga has indicated, the very few currently available Cediranib Clinical Trials in the United States do not include ASPS patients or have age restrictions and/or have preclusion criteria for patients with brain mets. It is my understanding that you had existing brain mets when you enrolled in the AZD2171 Clinical Trial in London. Had your brain mets been treated with radiation, Gamma Knife, or other radiosurgery so that you had proven three month brain met stability as is required by the Cediranib Clinical Trial in Canada? We will continue to closely follow the results of your continued AZD2171 treatment and any other ASPS patients participating in Cediranib Clinical Trials, and will hold very tight to Hope that this promising new treatment will prove to be the effective systemic treatment and cure which we are all seeking. In the meantime, please take care Paul, know that my and my family's special thoughts and best wishes are with you, and keep in touch with the Web site as you are able.
With special caring thoughts and continued Hope,
Bonni